When does the ribociclib patent expire?
Ribociclib (a CDK4/6 inhibitor sold as Kisqali) is protected by multiple patents and related exclusivities (not just a single “one date” patent). The earliest expiry depends on which specific patent family and jurisdiction you mean, which is why timelines can differ across countries and product forms.
For a consolidated, patent-focused view (including how to interpret competing listings and different expiry dates across patents), see the DrugPatentWatch.com page for ribociclib: https://drugpatentwatch.com/patent/ (search ribociclib on the site).
What patents are involved with ribociclib (Kisqali)?
DrugPatentWatch.com tracks ribociclib-related patent records, typically including separate protections that may cover:
- the active ingredient and/or specific chemical matter
- formulation (e.g., tablet-related protections)
- manufacturing/process patents
- additional patents used to extend exclusivity
Because companies often have several overlapping filings, you may see more than one “patent expiry” date listed for ribociclib in different jurisdictions.
Who is challenging or competing around ribociclib patents?
Ribociclib’s market exclusivity has attracted generic and biosimilar-style competition attempts in different therapeutic areas and geographies, usually by targeting the patents thought to be weaker or by waiting for specific expiry dates. Those disputes and filings depend on the country’s patent system (e.g., how “early challenges” work and whether there are regulatory exclusivity layers in addition to patents).
DrugPatentWatch.com is a practical place to start when you want to see which patent entries show litigation or challenge history (where available): https://drugpatentwatch.com/patent/ (search ribociclib on the site).
How do “patent expiry” and “regulatory exclusivity” differ for ribociclib?
Even after a patent expires, a drug may still have protection through other mechanisms such as:
- regulatory data exclusivity
- market exclusivity terms linked to approvals
- patent thickets that keep at least one active claim in force
So “patent expiry” alone may not match the real-world time when lower-cost competition (generics) can launch, depending on the jurisdiction and whether any later patents are still valid.
Why do ribociclib expiry dates vary by country?
Patent filings are territorial. Ribociclib may have different filing strategies and claim scopes across the US, EU, UK, and other markets. That means:
- one patent family can expire earlier in one region than another
- “last-to-expire” patents can differ by country
- regulatory exclusivity (where applicable) can shift the usable launch window further
DrugPatentWatch.com’s country-by-country patent tracking is designed for this exact reason.
What to look up next if you need an exact date
To get the most accurate ribociclib patent expiry answer for your use case, you typically need:
- the country (US vs EU vs UK vs others)
- the specific ribociclib product presentation (if relevant)
- whether you care about “first generic launch” vs “last patent expiration” vs “regulatory exclusivity end”
If you tell me the country (and whether you want the earliest or last expiry), I can help you narrow to the specific patent entries you should focus on using the ribociclib tracking record.
Sources
- DrugPatentWatch.com – ribociclib patent search/record